Savage Martin O, Bang Peter
Department of pediatric endocrinology William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, London, UK.
Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S178-84. doi: 10.4103/2230-8210.104034.
Growth hormone (GH) is widely prescribed for children with short stature across a range of growth disorders. We describe the variability of responses seen in conditions approved for GH therapy. Although responses in different growth disorders are satisfactory, evidence is increasing for an unacceptably high rate of poor or unsatisfactory response (i.e., not leading to significant catch-up growth) in terms of change in height standard deviation score and height velocity. Consequently, there is a need to define a poor response and to prevent or correct it by optimizing treatment regimens. This review discusses the optimal investigation of the child who is a candidate for GH therapy so that a diagnosis-based guide to therapy and dosage can be made. The relevant parameters in the evaluation of growth response are described together with the definitions of a poor response.
生长激素(GH)被广泛用于治疗各种生长障碍的身材矮小儿童。我们描述了在批准使用GH治疗的疾病中所观察到的反应变异性。尽管在不同生长障碍中的反应是令人满意的,但越来越多的证据表明,就身高标准差评分和身高增长速度的变化而言,不良或不满意反应(即未导致显著追赶生长)的发生率高得令人无法接受。因此,有必要定义不良反应,并通过优化治疗方案来预防或纠正它。本综述讨论了对GH治疗候选儿童的最佳评估,以便制定基于诊断的治疗和剂量指南。文中描述了生长反应评估中的相关参数以及不良反应的定义。